CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired Retrogenix Limited for $53.9 million, net of $8.5 million cash (plus up to $6.9 million contingent), a transaction completed in March 2021, structured as all cash.
Retrogenix Limited operates in Discovery and Safety Assessment (DSA), is based in United Kingdom. Retrogenix Limited was an early-stage CRO providing specialized bioanalytical services utilizing its proprietary cell microarray technology.
The acquisition of Retrogenix enhances our scientific expertise with additional large molecule and cell therapy discovery capabilities. The purchase price of Retrogenix was $53.9 million, net of $8.5 million in cash.
DSA segment, large-molecule discovery
The acquisition of Retrogenix enhances our scientific expertise with additional large molecule and cell therapy discovery capabilities. The purchase price of Retrogenix was $53.9 million, net of $8.5 million in cash.Charles River FY2021 10-K, Business Acquisitions note
Advisory firms were not disclosed for this transaction.